GLI1 Gene Alterations in Neoplasms of the Genitourinary and Gynecologic Tract.

TitleGLI1 Gene Alterations in Neoplasms of the Genitourinary and Gynecologic Tract.
Publication TypeJournal Article
Year of Publication2022
AuthorsArgani P, Boyraz B, Oliva E, Matoso A, Gross J, Fridman E, Zhang L, Dickson BC, Antonescu CR
JournalAm J Surg Pathol
Volume46
Issue5
Pagination677-687
Date Published2022 May 01
ISSN1532-0979
KeywordsAdult, Aged, Aged, 80 and over, Biomarkers, Tumor, Endometrial Neoplasms, Female, Gene Fusion, Glomus Tumor, Humans, Middle Aged, Sarcoma, Endometrial Stromal, Uterine Neoplasms, Zinc Finger Protein GLI1
Abstract

We report 4 neoplasms of the kidney (2 cases) and uterus (2 cases) harboring rearrangements or amplifications of the GLI1 gene, which because of their unusual clinical presentation, morphology, and immunoprofile mimicked other neoplasms, causing significant diagnostic challenge. The neoplasms occurred in 4 female patients ages 33 to 88 years. Histologically they all demonstrated nodular growth, solid architecture, bland epithelioid to ovoid-spindle cells with pale cytoplasm set in a variably myxoid or hyalinized stroma. One uterine tumor also demonstrated a focal round cell pattern, while another demonstrated focal pleomorphism. Unlike most previously reported neoplasms with these genetic abnormalities, the neoplasms in the current series were negative for S100 protein and minimally reactive for actin. All labeled for CD10 and cyclin D1, while 2 labeled for estrogen receptor and BCOR and 1 labeled for desmin, raising consideration of endometrial stromal sarcoma, myxoid leiomyosarcoma, metastatic breast carcinoma, and glomus tumor. One renal neoplasm demonstrated a GLI1-FOXO4 gene fusion and the other harbored a GLI1 gene rearrangement (unknown partner). The 2 uterine neoplasms exhibited GLI1 gene amplifications. GLI1-altered neoplasms (particularly those with GLI1 amplification) show variable morphology and lack a consistent immunophenotype, and thus may trigger diagnostic challenges which can be resolved by molecular testing.

DOI10.1097/PAS.0000000000001844
Alternate JournalAm J Surg Pathol
PubMed ID34907995
PubMed Central IDPMC9018467
Grant ListP30 CA008748 / CA / NCI NIH HHS / United States
P50 CA140146 / CA / NCI NIH HHS / United States
P50 CA217694 / CA / NCI NIH HHS / United States
Related Faculty: 
Baris Boyraz, M.D., Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700